New Three-Drug attack on tough stomach cancer cases
NCT ID NCT07149090
Summary
This trial is testing whether adding a drug called lenvatinib to standard immunotherapy and chemotherapy can help people with advanced stomach cancer that has spread to the lining of the abdomen and caused significant fluid buildup. The study aims to find a safe dose and see if this combination improves how long patients live without their cancer getting worse. It is for adults newly diagnosed with this specific type of metastatic stomach cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.